Compare Bank of America Corp (BAC) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Cassava Sciences Inc — how do they compare? Bank of America Corp trades at $64.06 (market cap $446.56B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Bank of America Corp is far larger — about 9352× Cassava Sciences Inc's market cap, and Bank of America Corp pays a 2% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BAC | FLNA | |
|---|---|---|
Market Cap | $446.56B | $47.75M |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $64.00 | $4.64 |
52-Week Low | $46.72 | $0.87 |
Dividend Yield | 2% | — |
Enterprise Value | — | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $64.00, up 1.31% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals, including a P/E of 14.75 and net income margin of 28.21%, supported by revenue growth to $113.10 billion in 2025. Recent news highlights partnerships, hiring initiatives, and positive analyst coverage, with a consensus price target of $67.36.
Outlook remains positive with potential upside from capital returns and earnings growth, though risks include macroeconomic sensitivity and high RSI levels. Analyst consensus is strongly bullish with 64.82% buy ratings, indicating confidence in BAC's deposit franchise and operational strength amid evolving rate cycles.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
